TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01746784
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
Study: NCT01233375
Drug: CO-1.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles.
Study: NCT02037711
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
Study: NCT04523090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills with no active ingredient.
Study: NCT01823835
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
Study: NCT02317809
Drug: Liquid pergoveris
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
Study: NCT01114360
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
Study: NCT01114360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
Study: NCT01919424
Drug: Methacholine Chloride
Normalized name: Methacholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma
Study: NCT00266344
Drug: Placebo / Duration of Treatment 3 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03605069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be applied topically once daily for 8 weeks of treatment.
Study: NCT02811783
Drug: Placebo Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TID for 2 weeks
Study: NCT03732365
Drug: Standard of Care Antibiotic Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
Study: NCT04384523
Drug: OsrHSA 20 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
Study: NCT04384523
Drug: OsrHSA 40 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
Study: NCT04384523
Drug: OsrHSA 80 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
Study: NCT04384523
Drug: OsrHSA 140 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
Study: NCT04384523
Drug: OsrHSA 200 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
Study: NCT00689793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.
Study: NCT03658070
Drug: XY0206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
Study: NCT02981966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for dapagliflozin
Study: NCT00854503
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/day in one oral administration
Study: NCT00854503
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg/day in one oral administration.
Study: NCT00797992
Drug: Injection
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg bevacizumab
Study: NCT00026377
Drug: SU5416
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion at assigned dose
Study: NCT02391961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
Study: NCT04621487
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 days 500 mg bid
Study: NCT04621487
Drug: according to antibiogram
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to antibiogram
Study: NCT03400631
Drug: Aspiration 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration only at time 0
Study: NCT03400631
Drug: Dextrose 1
Normalized name: DEXTROSE 10% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose injection at week 1
Study: NCT03400631
Drug: Aspiration 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration only at week 1
Study: NCT01417832
Drug: Resin infiltration / adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
Study: NCT01417832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
Study: NCT04405271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 1 tablet per day will be administered for a total of 12 weeks.
Study: NCT01248871
Drug: procedure:sevoflurane-remifentanil/sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT01248871
Drug: propofol-remifentanil/sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT00049595
Drug: ABVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00049595
Drug: BEACOPP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00049595
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00049595
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04216355
Drug: CAG Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term CAG derived regimen
Study: NCT03331523
Drug: Taclonex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
Study: NCT03331523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
Study: NCT00566254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02635997
Drug: antiresorptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00357383
Drug: Azithromycin (T1225)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00134381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
Study: NCT03692416
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Study: NCT04223609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone-matched placebo tablet
Study: NCT02645617
Drug: Varnish
Normalized name: dental polish-varnishes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application to the teeth
Study: NCT00735371
Drug: LDX 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Study: NCT00735371
Drug: LDX 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Study: NCT00735371
Drug: LDX 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Study: NCT00735371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical to test product.
Study: NCT01875718
Drug: UC1010
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01875718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01808885
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule shells with identical appearance as the active compound TRO19622
Study: NCT00351182
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00351182
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00718341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01188577
Drug: Epinephrine Inhalation Aerosol, HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
Study: NCT01188577
Drug: Epinephrine Inhalation Aerosol
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
Study: NCT04419688
Drug: STT-5058
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal Antibody STT-5058
Study: NCT04419688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to STT-5058
Study: NCT01245673
Drug: Revlamid® (Lenalidomide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
Study: NCT00354172
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
Study: NCT01640665
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
Study: NCT02699372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05330650
Drug: Coated Vicryl+
Normalized name: VICRYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
Study: NCT05330650
Drug: Vicryl
Normalized name: VICRYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
Study: NCT02699372
Drug: RO6889450
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02528357
Drug: GSK3174998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
Study: NCT01397604
Drug: GLA-AF
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
Study: NCT01142024
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
Study: NCT03691779
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet orally once daily in the morning.
Study: NCT00267150
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental
Study: NCT01864161
Drug: gluconate iron
Normalized name: IRON (AS FERROUS GLUCONATE)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
Study: NCT01864161
Drug: Liposomal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sideral forte 30 mg/die
Study: NCT02068560
Drug: dDAVP infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04482569
Drug: XNW4107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
Study: NCT00957437
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral Dose, ER formulation 1
Study: NCT00957437
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER formulation 1, bid for 5 days
Study: NCT00957437
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral Dose, ER formulation 2
Study: NCT00806468
Drug: Desmotabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
Study: NCT00167934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given at same frequency as Valproate
Study: NCT02983422
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
Study: NCT06312033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
Study: NCT02051023
Drug: FML 0.1% eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
Study: NCT02051023
Drug: Liquifilm artificial tears eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquifilm instillation 4 times a day for 22 days
Study: NCT00496132
Drug: PRO131921
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses by IV infusion
Study: NCT01228292
Drug: Citrasate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrasate is infused as a dialysate
Study: NCT01760811
Drug: Erbitux,merck serono
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
Study: NCT03327168
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
Study: NCT01027260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dosing
Study: NCT00710242
Drug: DF01
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
Study: NCT00710242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
Study: NCT03006302
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
Study: NCT00782613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a cream formulation
Study: NCT01925300
Drug: Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab
Normalized name: rosuvastatin calcium 20 MG [Crestor]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00861211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00048750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00167661
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
Study: NCT03536039
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose of 50 mg/mq
Study: NCT03536039
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose of 750 mg/mq
Study: NCT00918554
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
Study: NCT00918554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
Study: NCT00005669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control capsules for metformin
Study: NCT00424268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02253810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution